Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153344 | 0.79 | — | — | |
| SCHEMBL13308899 | 0.77 | — | — | |
| SCHEMBL21376036 | 0.77 | — | — | |
| SCHEMBL24152800 | 0.77 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL28873183 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL1273245 | 0.75 | CYP2D6 (0.50) | CYP2D6CYP2C19MMP1MMP8CNR2 | |
| SCHEMBL387346 | 0.72 | — | — | |
| SCHEMBL20436905 | 0.72 | — | — | |
| SCHEMBL9483208 | 0.72 | — | — | |
| SCHEMBL6440850 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009772-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-01-11 | — | — | US | claimed |
| US-20150344448-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2015-12-03 | — | — | US | claimed |
| WO-2014116594-A1 | HIGHLY SELECTIVE ANTI-CANCER AGENTS TARGETING NON-SMALL CELL LUNG CANCER AND OTHER FORMS OF CANCER | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | WO | claimed |
| JP-3739785-B2 | — | — | 2006-01-25 | — | — | JP | claimed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | claimed |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | FROEHLER BRIAN (US) | 2003-09-11 | — | — | US | claimed |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| US-10392354-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | THE UNIVERSITY OF TOLEDO (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190023671-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2019-01-24 | — | — | US | disclosed |
| US-10138216-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180009772-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-01-11 | — | — | US | disclosed |
| US-9862692-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | THE UNIVERSITY OF TOLEDO (US) | 2018-01-09 | — | — | US | disclosed |
| EP-0616612-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993024507-A1 | CONFORMATIONALLY RESTRAINED OLIGOMERS CONTAINING AMIDE OR CARBAMATE LINKAGES FOR SEQUENCE-SPECIFIC BINDING | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024508-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993012135-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023671-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EML4, DCK | CYP2D6 4045/4885CYP2C19 3270/4885MMP1 4554/4885 |
| US-20030170680-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | CYP2D6 4088/4885CYP2C19 4860/4885MMP1 4614/4885 |
| US-10392354-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EML4, DCK | CYP2D6 4111/4885CYP2C19 3376/4885MMP1 4550/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | CYP2D6 4088/4885CYP2C19 4860/4885MMP1 4614/4885 |
| US-20180009772-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EML4, DCK | CYP2D6 4045/4885CYP2C19 3270/4885MMP1 4554/4885 |
| US-10138216-B2 | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EML4, DCK | CYP2D6 4045/4885CYP2C19 3270/4885MMP1 4554/4885 |
| US-20030096980-A1 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | NUDT1, DHX15, DDX5 | CYP2D6 4088/4885CYP2C19 4860/4885MMP1 4614/4885 |
| US-20150344448-A1 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EML4, DCK | CYP2D6 4045/4885CYP2C19 3270/4885MMP1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.